The search for an effective coronavirus vaccine is widely noted as one of the keys to helping the world return to general after the devastating effects of the pandemic.
The UK now has access to six other covid-19 vaccine applicants in development, in 4 other types, representing about 340 million doses, the Astra Zeneca-Oxford University vaccine trial was briefly discontinued this month after a side effect was reported on a patient. . United Kingdom.
A week ago (12 September), he revealed that the trial would resume at all sites in the UK, as stated through the University of Oxford: “Ongoing randomized controlled clinical trials of the Oxford ChAdOx1 nCoV-19 coronavirus vaccine will fully resume clinical trial sites in the UK. “
Worldwide, another 18,000 people obtained the test vaccines as part of the trial.
The university said that “in giant trials like this, some participants are expected not to feel well and each case will be thoroughly evaluated to ensure careful protection assessment. “
He added that the university may simply disclose medical data on the disease “for reasons of confidentiality of the participants. “
“We are committed to ensuring the protection of our participants and assembling the criteria for conduct in our studies and will continue to strictly monitor protection,” the university added.
At a Downing Street briefing earlier this month, UK lead clinical adviser Sir Patrick Vallance said there is a “reasonable chance” that a vaccine will be obtained next year.
Receive the latest updates from all over Greater Manchester in your inbox with the MEN newsletter
You can log in by following the commands here
Sir Patrick told a press convention in Downing Street that of the 200 vaccine projects around the world, six are in “final stages of testing. “
He said many show the “right immune response. “
“This is a big step on the road to vaccine production,” Sir Patrick said at the briefing.
“I hope that until the end of the year we have indications that some are working and have the right protection profile.
“I think there’s a moderate option that we can think about the vaccination option next year at the higher levels. “
Speaking in the Commons on Thursday (September 17) after pronouncing blockade measures in the Northeast, Matt Hancock asked when a vaccine will be launched.
He replied: “Of course, we will only allow a vaccine to be implemented to all grades when it is, and the MHRA (Medicines and Healthcare Products Regulatory Agency) is one of the most reputable and quality regulators in the world.
“They are the ones who will take the decision on whether it is about factoring a license – and of course the consultation of who deserves to be vaccinated and in what order becomes a clinical resolution on which we will take the opinion of the Board. Committee on Vaccines and Immunizations”.
Priority teams, such as frontline fitness workers, others with serious illnesses, the elderly, and BAME teams are the first to get a vaccine if a vaccine is approved.
Last month, Australia ordered 25 million doses of the Covid-19 vaccine developed through Oxford University in partnership with pharmaceutical company AstraZeneca, the country’s minister said.
In the UK, South Africa and Brazil, 3 large-scale trials are being conducted to verify its effectiveness in protecting against the virus.
Australian Prime Minister Scott Morrison promised to make the vaccine “as much as possible” in an interview with Melbourne radio station 3AW, before visiting AstraZeneca’s laboratory in Sydney.
He said at the time: “Today is a day of hope and Australia wants hope, the world wants hope, when it comes to this coronavirus. “
“And if we were able to pass the tests, we hope it’s ready by early next year. If it can be done sooner, much better.
In another radio interview, Morrison said he had recently spoken to French leader Emmanuel Macron about how the AstraZeneca vaccine is “one of the most productive customers in the world today. “
The UK government has received up to one hundred million doses of the AstraZeneca vaccine.
And the government announced earlier this month that it had reached agreements that it said would quickly give British citizens 90 million doses of two other possible vaccines opposed to Covid-19.
Vaccines are developed through us biotechnology company Novavax and Belgium-based pharmaceutical company Janssen.
As a component of the agreements in principle, the UK has received 60 million doses of the Novavax vaccine, supporting a clinical trial with the National Institute of Health Research (NIHR).
Some 30 million doses of Janssen were received and ministers agreed in principle to co-finance a global clinic for their vaccine.
The non-profit Janssen vaccine is expected to begin the next phase of clinical trials later this year and read about whether two doses can provide long-term coverage against coronavirus.
Meanwhile, Novavax plans to manufacture some of its vaccines at the Fujifilm Diosynth Biotechnologies facility in Billingham, Stockton-on-Tees in the Northeast, will be available.
The government has stated that if Novavax and Janssen vaccines are found to be a success in clinical trials, they may be sent to the UK until mid-2021.
Kate Bingham, chair of the government’s vaccine task force, cautioned that it is not clear that any vaccine is effective.
She said: “The challenge is that we know which of these vaccines, if any, can work because there has been no vaccine that opposes a human coronavirus. “
“So what we’re doing is selecting six of the most promising vaccines from 4 other types of vaccines and we expect one of them to work.
“It would be a smart position if everyone worked, but it’s not likely. The truth is that the maximum will fail and we must be sure that if any of them prove to be effective and safe, we have the right to do so.
Ms. Bingham said she was “reasonably sure” that a vaccine would be discovered that would decrease the severity of coronavirus symptoms and decrease deaths.
And the Director-General of the World Health Organization had a sobering message when he warned that there will never be a miraculous cure for the coronavirus pandemic.
Dr. Tedros Adhanom Ghebreyesus said at a press conference: “Several vaccines are lately in phase 3 of clinical trials and we all hope to have a number of effective vaccines that can save you infection. “
He added: “However, there is no quick fix right now and there may never be. “
His comments are an assembly of the emergency committee of foreign experts convened through WHO.
The leading medical officer described this as a “moment of reflection,” noting that it happened six months after the coronavirus outbreak declared a public fitness emergency of foreign concern.